Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-B98 in PD-1/L1-refractory extensive-stage small cell lung cancer
2023-507687-38-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab, lenvatinib, favezelimab, quavonlimab, mk-4830 and 1 more in small cell lung cancer (SCLC) (5 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Experiencing Dose-Limiting Toxicities, Number of Participants Who Experience at Least One Adverse Event and 2 more. Planned start Aug 2021; status: authorised.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2023-507687-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507687-38-00.